Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Sarcoma 2Lung Neoplasms 2Head and Neck Neoplasms 2Melanoma 1Glioma 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 166Nivolumab 111Ipilimumab 93Dacarbazine 44trametinib 36dabrafenib 34Vemurafenib 33binimetinib 23atezolizumab 23Temozolomide 21cemiplimab 18Paclitaxel 18encorafenib 17spartalizumab 16cobimetinib 15Carboplatin 14talimogene laherparepvec 13Cisplatin 13Cyclophosphamide 12lenvatinib 10Pemetrexed 10Gemcitabine 10Docetaxel 10durvalumab 9Drug Therapy 9Bevacizumab 9tremelimumab 8Injections 8Albumin-Bound Paclitaxel 8130-nm albumin-bound paclitaxel 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Melanoma × AH 111585 × Clear all
NCT00565721 2014-08-18

A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis

GE Healthcare

Phase 2 Completed
33 enrolled 23 charts
CNSDermatologicHead & NeckSarcomaThoracic

Glioma, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡